GRAL

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

37.030

Open

36.170

VWAP

36.07

Vol

364.94K

Mkt Cap

1.27B

Low

35.200

Amount

13.16M

EV/EBITDA(TTM)

Total Shares

35.30M

461.68M

EV/OCF(TTM)

P/S(TTM)

8.51

GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.

3 Analyst Rating

-26.60% Downside

Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 26.00 USD with a low forecast of 20.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

-26.60% Downside

Current: 35.420

Low

20.00

Averages

26.00

High

32.00

-26.60% Downside

Current: 35.420

Low

20.00

Averages

26.00

High

32.00

Canaccord Genuity

Kyle Mikson

Strong Buy

Initiates

$32

2025-04-21

Reason

Canaccord Genuity

Kyle Mikson

Price Target

$32

2025-04-21

Initiates

Strong Buy

Reason

Morgan Stanley

Tejas Savant

Hold

Maintains

$16 → $20

2025-03-18

Reason

Morgan Stanley

Tejas Savant

Price Target

$16 → $20

2025-03-18

Maintains

Hold

Reason

Morgan Stanley analyst Tejas Savant raised the firm's price target on Grail to $20 from $16 and keeps an Equal Weight rating on the shares following what the firm calls a "solid quarter." 2025 guidance was in-line with the preliminary view and consistent with prior commentary calling for more moderate screening growth ahead of reimbursement, notes the analyst, who adds that the launch of Galleri v2 expected to lead to significant cost of goods sold improvement over time as test volumes scale.

Morgan Stanley

Tejas Savant

Hold

Initiates

$16

2024-11-27

Reason

Morgan Stanley

Tejas Savant

Price Target

$16

2024-11-27

Initiates

Hold

Reason

Morgan Stanley initiated coverage of Grail with an Equal Weight rating and $16 price target. The company's Galleri multi-cancer early detection screening test has the potential to address a significant unmet need, the analyst tells investors in a research note. The firm says that while Grail's cash preservation efforts are encouraging, with Medicare reimbursement, the key catalyst to unlocking share value, essentially a 2027 dynamic, the stock's near-term risk/reward is balanced.

Guggenheim

Subbu Nambi

Hold

Initiates

n/a

2024-10-17

Reason

Guggenheim

Subbu Nambi

Price Target

n/a

2024-10-17

Initiates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Grail Inc (GRAL.O) is -2.26, compared to its 5-year average forward P/E of -0.96. For a more detailed relative valuation and DCF analysis to assess Grail Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.96

Current PE

-2.26

Overvalued PE

-0.01

Undervalued PE

-1.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.27

Current EV/EBITDA

-1.14

Overvalued EV/EBITDA

0.34

Undervalued EV/EBITDA

-0.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

3.65

Current PS

7.45

Overvalued PS

6.94

Undervalued PS

0.36